COVID‐19 and ischemic stroke

DOI Web Site Web Site 1 Citations
  • Dimitrios Sagris
    Department of Internal Medicine Faculty of Medicine School of Health Sciences University of Thessaly Larissa Greece
  • Aikaterini Papanikolaou
    Department of Internal Medicine Faculty of Medicine School of Health Sciences University of Thessaly Larissa Greece
  • Alexandra Kvernland
    Department of Neurology NYU Grossman School of Medicine New York NY USA
  • Eleni Korompoki
    Department of Clinical Therapeutics National and Kapodistrian University of Athens Athens Greece
  • Jennifer A. Frontera
    Department of Neurology NYU Grossman School of Medicine New York NY USA
  • Andrea B. Troxel
    Department of Population Health NYU Grossman School of Medicine New York NY USA
  • Maria Gavriatopoulou
    Department of Clinical Therapeutics National and Kapodistrian University of Athens Athens Greece
  • Haralampos Milionis
    Department of Internal Medicine Faculty of Medicine School of Health Sciences University of Ioannina Ioannina Greece
  • Gregory Y. H. Lip
    Liverpool Centre for Cardiovascular Science University of Liverpool and Liverpool Heart & Chest Hospital Liverpool UK
  • Patrik Michel
    Stroke Center Neurology Service Lausanne University Hospital Lausanne Switzerland
  • Shadi Yaghi
    Department of Neurology NYU Grossman School of Medicine New York NY USA
  • George Ntaios
    Department of Internal Medicine Faculty of Medicine School of Health Sciences University of Thessaly Larissa Greece

Description

<jats:title>Abstract</jats:title><jats:p>Since the onset of the COVID‐19 pandemic, a substantial proportion of COVID‐19 patients had documented thrombotic complications and ischemic stroke. Several mechanisms related to immune‐mediated thrombosis, the renin angiotensin system and the effect of SARS‐CoV‐2 in cardiac and brain tissue may contribute to the pathogenesis of ischemic stroke in patients with COVID‐19. Simultaneously, significant strains on global healthcare delivery, including ischemic stroke management, have made treatment of stroke in the setting of COVID‐19 particularly challenging. In this review, we summarize the current knowledge on epidemiology, clinical manifestation, and pathophysiology of ischemic stroke in patients with COVID‐19 to bridge the gap from bench to bedside and clinical practice during the most challenging global health crisis of the last decades.</jats:p>

Journal

Citations (1)*help

See more

Report a problem

Back to top